Standout Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck 2006 2026 2012 2019 3.6k
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (2006)
    James A. Bonner, Paul M. Harari et al. New England Journal of Medicine
  2. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt (2006)
    Kathryn O’Reilly, Qing‐Bai She et al. Cancer Research
  3. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013)
    Min Yu, Aditya Bardia et al. Science
  4. A view on drug resistance in cancer (2019)
    Neil Vasan, José Baselga et al. Nature
  5. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (2015)
    Sandra M. Swain, José Baselga et al. New England Journal of Medicine
  6. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival (2009)
    James A. Bonner, Paul M. Harari et al. The Lancet Oncology
  7. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer (2008)
    Arkaitz Carracedo, Li Ma et al. Journal of Clinical Investigation
  8. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996)
    José Baselga, Debu Tripathy et al. Journal of Clinical Oncology
  9. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998)
    Mark D. Pegram, A. Lipton et al. Journal of Clinical Oncology
  10. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer (2013)
    Weiyi Toy, Yang Shen et al. Nature Genetics
  11. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy (2007)
    Jan B. Vermorken, José Trigo et al. Journal of Clinical Oncology
  12. The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy (2006)
    Maurizio Scaltriti, José Baselga Clinical Cancer Research
  13. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study (2013)
    Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology
  14. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (2017)
    David Cameron, Martine Piccart et al. The Lancet
  15. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations (2008)
    Violeta Serra, Ben Markman et al. Cancer Research
  16. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors (2011)
    Johanna C. Bendell, Jordi Rodón et al. Journal of Clinical Oncology
  17. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes (2017)
    Catherine C. Coombs, Ahmet Zehir et al. Cell stem cell
  18. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer (2009)
    José Baselga, Semiglazov Vf et al. Journal of Clinical Oncology
  19. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer (2017)
    Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research
  20. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (2017)
    Véronique Dièras, David Miles et al. The Lancet Oncology
  21. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab (2015)
    Roberto Salgado, Carsten Denkert et al. JAMA Oncology
  22. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 (2014)
    Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology
  23. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013)
    Denise A. Yardley, Shinzaburo Noguchi et al. Advances in Therapy
  24. Genome doubling shapes the evolution and prognosis of advanced cancers (2018)
    Craig M. Bielski, Ahmet Zehir et al. Nature Genetics
  25. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018)
    Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 22 from Science/Nature 167 standout
Sub-graph 1 of 15

Citing Papers

CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
Head and Neck Cancer
2020 Standout
44 intermediate papers

Works of José Baselga being referenced

A view on drug resistance in cancer
2019 StandoutNature
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
and 20 more

Author Peers

Author Last Decade Papers Cites
José Baselga 25287 13824 19503 482 45.7k
José Baselga 34173 13302 17049 270 48.4k
Janet Dancey 19412 15054 8425 202 37.3k
Jaap Verweij 27869 21972 13557 619 54.4k
Roy S. Herbst 31201 25944 16614 573 49.6k
Eric K. Rowinsky 18262 9456 11946 392 31.5k
John D. Hainsworth 21144 12105 9981 623 36.4k
Richard Kaplan 22048 19835 7159 171 45.0k
Heikki Joensuu 12609 11879 8283 570 34.2k
David L. Rimm 19402 7717 17663 541 40.3k
Howard A. Burris 25010 10502 12786 737 37.4k

All Works

Loading papers...

Rankless by CCL
2026